Portal de Periódicos da CAPES

The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia

1987; Wiley; Volume: 65; Issue: 1 Linguagem: Inglês

10.1111/j.1365-2141.1987.tb06130.x

1365-2141

Junia V. Melo, Daniel Catovsky, Walter M. Gregory, David A. G. Galton,

Immunodeficiency and Autoimmune Disorders

Summary The prognostic value of biological, clinical and laboratory features was analysed in a series of 265 patients with chronic lymphocytic leukaemia (CLL) and prolymphocytic leukaemia (PLL). On univariate analysis seven features were shown to influence significantly the survival of the whole group of patients: absolute prolymphocyte count (ABS PROL), percentage of prolymphocytes (%PROL), WBC, spleen size, age, intensity of surface‐membrane immunoglobulin (SmIg) and mouse (M) rosettes. Multivariate regression analysis of these features showed that only ABS PROL and spleen size had independent prognostic significance. The survival in PLL (38 cases) was significantly shorter than in CLL (227 cases) (median survival=3 and 8 years, respectively). Patients with CLL with an increased %PROL (11–55%), defined as CLL/PL, could be divided into two groups: those with ABS PROL ≤ 15 × 10 9 /1 (26 cases) fell within the ‘standard‐prognostic risk’ for typical CLL (i.e. ≤ 10% PROL), whereas the survival outlook for the cases with ABS PROL > 15 × 10 9 /1 (40 cases) was as bad as for PLL. A scoring system was generated with the four features that showed high prognostic significance: ABS PROL, spleen size, SmIg and M‐rosettes. The score proved to be superior to any single feature as a predictor of survival, being especially useful in the analysis of the CLL/PL group: cases with high scores (>2) had a median survival of 2·5 years, while the median has not been reached for those with low scores (≤2). We suggest that this scoring system may help to identify the cases of CLL/PL that behave as PLL, and as such may benefit from different treatment.